Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT03739710
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Elizabeth Davis
- Target Recruit Count
- 2
- Registration Number
- NCT03724968
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 15
- Registration Number
- NCT03719131
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT03711188
- Locations
- 🇬🇧
The Christie Hospital, Manchester, United Kingdom
🇬🇧St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2020-07-02
- Target Recruit Count
- 3
- Registration Number
- NCT03707457
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT03693846
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-02-15
- Target Recruit Count
- 19
- Registration Number
- NCT03663166
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸UNC Limeberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Duke University, Durham, North Carolina, United States
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 30
- Registration Number
- NCT03650894
- Locations
- 🇺🇸
Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 262
- Registration Number
- NCT03647969
- Locations
- 🇩🇪
Klinikum Aschaffenburg, Aschaffenburg, Germany
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Klinikum St. Marien Amberg, Amberg, Germany
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT03646617
- Locations
- 🇺🇸
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
🇺🇸Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Lancaster General Hospital, Lancaster, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.